Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAMY K METYAS

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1831104694
CMS profile
128377
Location
COVINA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$282,924.31

604 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 8 of 13; records 351–400 of 604 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAMY K METYAS

NPI 1831104694 · CMS profile ID 128377

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

COVINA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 8 of 13; records 351–400 of 604 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1831104694?year=2019&recipient=provider&page=8#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAMY K METYAS, NPI 1831104694, CMS profile ID 128377. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 13; records 351–400 of 604 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831104694?year=2019&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SAMY K METYAS, NPI 1831104694, CMS profile ID 128377. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 13; records 351–400 of 604 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831104694?year=2019&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SAMY K METYAS, NPI 1831104694, CMS profile ID 128377, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 8 of 13; records 351–400 of 604 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1831104694?year=2019&recipient=provider&page=8#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

604 matching records · $282,924.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 604 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 351–400 of 604.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $18.9506/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673437043 CMS
GENZYME CORPORATION $24.9506/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694094023 CMS
Horizon Therapeutics plc $2,448.0006/12/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691445549 CMS
Horizon Therapeutics plc $125.6806/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691445553 CMS
Mallinckrodt Enterprises LLC $2.1106/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704809895 CMS
Mallinckrodt Enterprises LLC $21.0006/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704809897 CMS
PFIZER INC. $18.1106/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672432433 CMS
E.R. Squibb & Sons, L.L.C. $5.4206/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651283235 CMS
Horizon Therapeutics plc $4.3306/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691445545 CMS
Celgene Corporation $761.6006/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672904562 CMS
Celgene Corporation $124.9006/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672904815 CMS
Celgene Corporation $2,873.0006/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672908113 CMS
Regeneron Healthcare Solutions, Inc. $3,255.0006/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673437023 CMS
UCB, Inc. $24.7706/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688290583 CMS
AbbVie, Inc. $2,000.0006/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647744799 CMS
Janssen Scientific Affairs, LLC $2,575.0006/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657601727 CMS
Novo Nordisk Inc $16.1406/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674444157 CMS
Janssen Biotech, Inc. $5.4506/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658594669 CMS
Janssen Biotech, Inc. $38.4706/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658594673 CMS
Janssen Scientific Affairs, LLC $562.6006/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657601723 CMS
Janssen Scientific Affairs, LLC $115.0006/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657601725 CMS
AbbVie, Inc. $15.8505/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647744599 CMS
AbbVie, Inc. $24.5505/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647744801 CMS
MEDEXUS PHARMA, INC. $15.8105/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673861201 CMS
E.R. Squibb & Sons, L.L.C. $10.7405/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651283233 CMS
AbbVie, Inc. $2,000.0005/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647744795 CMS
Amgen Inc. $33.6305/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663001053 CMS
ARBOR PHARMACEUTICALS, INC. $14.0205/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697366499 CMS
AbbVie, Inc. $445.9405/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647744797 CMS
Horizon Therapeutics plc $17.7205/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691445541 CMS
Mallinckrodt Enterprises LLC $1,850.0005/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704809893 CMS
Amgen Inc. $123.0605/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663000803 CMS
GENZYME CORPORATION $24.9505/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694054081 CMS
Grifols USA, LLC $17.6705/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692587449 CMS
Mallinckrodt Enterprises LLC $9.2505/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704809891 CMS
Amgen Inc. $8.6305/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663001059 CMS
Amgen Inc. $11.8505/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663001083 CMS
Janssen Scientific Affairs, LLC $860.0005/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657601721 CMS
PFIZER INC. $22.1005/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672433161 CMS
Mallinckrodt Enterprises LLC $26.0105/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704809889 CMS
Amgen Inc. $6.2505/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663000736 CMS
Horizon Therapeutics plc $22.3705/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691445535 CMS
Horizon Therapeutics plc $2,448.0005/15/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691445538 CMS
Janssen Biotech, Inc. $34.7705/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658594665 CMS
Lilly USA, LLC $575.0005/14/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658122733 CMS
PFIZER INC. $8.9605/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672437249 CMS
PFIZER INC. $5.3605/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672437235 CMS
PFIZER INC. $6.5205/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672441911 CMS
E.R. Squibb & Sons, L.L.C. $15.6305/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651283227 CMS
Horizon Therapeutics plc $2.9605/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691445531 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $282,924.31 604
PY2020 $104,777.19 358
PY2021 $87,965.00 373
PY2022 $126,816.19 390
PY2023 $225,955.19 462
PY2024 $220,041.11 479
PY2025 $230,022.55 441

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $20,419.16 2
PY2025 Principal investigator $3,432,728.17 53
PY2024 Recipient $104.58 1
PY2024 Principal investigator $3,345,685.96 90
PY2023 Principal investigator $813,878.89 118
PY2022 Recipient $314.00 1
PY2022 Principal investigator $1,354,175.08 247
PY2021 Recipient $65.00 1
PY2021 Principal investigator $1,151,466.83 155
PY2020 Recipient $825.80 2
PY2020 Principal investigator $803,381.38 113
PY2019 Principal investigator $737,702.55 112

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,517.39 12/17/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223289890
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,000.00 11/24/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment No dispute reported 06/30/2026 1190308938
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,938.81 11/19/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430932
Principal investigator 1 ABBVIE INC. $7,485.00 11/05/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1202522279
Principal investigator 1 GlaxoSmithKline, LLC. $5,853.60 11/05/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192187385
Principal investigator 1 ABBVIE INC. $8,200.00 10/30/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1202519775
Principal investigator 1 SANOFI US SERVICES INC. $500.00 10/22/2025 Non-covered Recipient Entity
Biovin Enterprises Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1226093105
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,205.58 10/22/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246430930
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,954.80 10/13/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246430946
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 10/10/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286703
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 10/10/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286705
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,812.52 10/02/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246430940
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,740.58 10/01/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286151
Principal investigator 1 SANOFI US SERVICES INC. $2,945.97 09/12/2025 Non-covered Recipient Entity
Biovin Enterprises Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1226093009
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,113.88 09/10/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430942
Principal investigator 1 American Regent $157,665.35 09/03/2025 Non-covered Recipient Entity
Biovin Enterprise LLC
TPX-100 No dispute reported 06/30/2026 1232689947
Principal investigator 1 GlaxoSmithKline, LLC. $2,926.80 09/03/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192187938
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $479.50 09/03/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223284919
Principal investigator 1 Novartis Pharmaceuticals Corporation $36,885.00 08/26/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy No dispute reported 06/30/2026 1190308940
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,225.94 08/20/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223284385
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28,296.00 08/18/2025 Non-covered Recipient Entity
Biovin Enterprises LLC Medvin Clinical Research
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220809669
Principal investigator 1 SANOFI US SERVICES INC. $462.00 08/15/2025 Non-covered Recipient Entity
Biovin Enterprises Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1226093024
Principal investigator 1 Amgen Inc. $143,671.00 08/13/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis No dispute reported 06/30/2026 1246644364
Principal investigator 1 SANOFI US SERVICES INC. $120.00 08/13/2025 Non-covered Recipient Entity
Biovin Enterprises Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1226093019
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $26,096.00 07/29/2025 Non-covered Recipient Entity
Biovin Enterprises LLC Medvin Clinical Research
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220809667
Principal investigator 1 Amgen Inc. $2,167.50 07/28/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246644351
Principal investigator 1 Amgen Inc. $146.33 07/28/2025 Non-covered Recipient Entity
SAMY METYAS MD INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246647597
Principal investigator 1 Eli Lilly and Company $17,892.00 07/07/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187880825
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $12,000.00 07/07/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430936
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $12,000.00 07/07/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430938
Principal investigator 1 Eli Lilly and Company $104,132.00 07/01/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187876121
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,000.00 06/25/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naive Subjects With Active Psoriatic Arthritis II (INSPIRE 2) No dispute reported 06/30/2026 1246430926
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,383.88 06/25/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430928
Principal investigator 1 Amgen Inc. $363,045.18 04/28/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639733
Principal investigator 1 Eli Lilly and Company $2,677.13 04/23/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187880821
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,563.70 04/23/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430944
Principal investigator 1 UCB SA $71,983.50 04/22/2025 Non-covered Recipient Entity
Medvin Clinical Research
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659474
Principal investigator 1 Amgen Inc. $156,750.68 04/18/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246639719
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 04/16/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223278128
Principal investigator 1 SANOFI US SERVICES INC. $3,408.75 04/09/2025 Non-covered Recipient Entity
Biovin Enterprises Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1226092972
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $208.22 03/26/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246430948
Principal investigator 1 Eli Lilly and Company $4,281.00 03/10/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874791
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,542.61 03/10/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246430934
Principal investigator 1 Eli Lilly and Company $10,436.00 02/18/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874789
Principal investigator 1 GlaxoSmithKline, LLC. $5,853.60 02/05/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192187380
Principal investigator 1 Eli Lilly and Company $159,180.00 02/04/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187880827
Recipient Amgen Inc. $10,872.75 01/29/2025 Covered Recipient Physician A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State No dispute reported 06/30/2026 1246637224
Principal investigator 1 Eli Lilly and Company $2,717.45 01/27/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187876175
Recipient Amgen Inc. $9,546.41 01/22/2025 Covered Recipient Physician A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246637226
Principal investigator 1 Eli Lilly and Company $52,953.00 01/21/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187880815
Principal investigator 1 Novartis Pharmaceuticals Corporation $96.24 01/15/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy No dispute reported 06/30/2026 1190301683
Principal investigator 1 Amgen Inc. $1,883,008.16 01/14/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246644381
Principal investigator 1 Eli Lilly and Company $4,890.30 01/09/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187880831
Principal investigator 1 Amgen Inc. $36,267.72 01/02/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH - COVINA
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246644343
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Medvin Clinical Research Covina
sGC activator in SSc patients No dispute reported 06/30/2026 1220679522